Histogenics (NASDAQ:HSGX) announced its earnings results on Thursday. The biotechnology company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.05), MarketWatch Earnings reports.
Shares of HSGX traded down $0.03 during mid-day trading on Friday, hitting $0.51. 1,795,036 shares of the company’s stock were exchanged, compared to its average volume of 8,070,151. Histogenics has a 52 week low of $0.50 and a 52 week high of $3.35. The stock has a market capitalization of $15.64 million, a PE ratio of -0.52 and a beta of 1.02.
A number of large investors have recently made changes to their positions in the stock. DRW Securities LLC bought a new position in Histogenics in the second quarter valued at approximately $242,000. Renaissance Technologies LLC increased its stake in Histogenics by 6.1% in the second quarter. Renaissance Technologies LLC now owns 384,329 shares of the biotechnology company’s stock valued at $961,000 after acquiring an additional 22,133 shares during the last quarter. BlackRock Inc. increased its stake in Histogenics by 72.0% in the second quarter. BlackRock Inc. now owns 54,753 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 22,927 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new position in Histogenics in the first quarter valued at approximately $320,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.
HSGX has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $3.50 target price on shares of Histogenics in a report on Monday, August 13th. Brookline Cap M reaffirmed a “buy” rating on shares of Histogenics in a report on Wednesday, August 1st. Needham & Company LLC raised their target price on shares of Histogenics to $5.00 and gave the stock a “buy” rating in a report on Thursday, September 6th. Zacks Investment Research cut shares of Histogenics from a “buy” rating to a “hold” rating in a report on Thursday, August 16th. Finally, BTIG Research cut shares of Histogenics from a “buy” rating to a “neutral” rating and set a $3.50 target price on the stock. in a report on Wednesday, September 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. Histogenics has a consensus rating of “Hold” and an average target price of $3.25.
ILLEGAL ACTIVITY NOTICE: “Histogenics (HSGX) Posts Quarterly Earnings Results, Misses Estimates By $0.05 EPS” was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/11/10/histogenics-hsgx-posts-quarterly-earnings-results-misses-estimates-by-0-05-eps.html.
Histogenics Company Profile
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Read More: How to Invest in a Bull Market
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.